Cardiac Risk from Prostate Cancer Treatment Explained
Androgen-deprivation therapy (ADT) with a gonadotropin-releasing hormone (GrRH) receptor agonist or GrRH antagonist plus radiotherapy is the cornerstone of treatment for prostate cancer. However, ADT increases cardiovascular disease (CVD) risk, making CVD the leading cause of death in men with prostate cancer. Now, the reasons for this have been explained.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Heart Advisor
Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
